WallStSmart

GE HealthCare Technologies Inc. (GEHC)vsGlobus Medical (GMED)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

GE HealthCare Technologies Inc. generates 602% more annual revenue ($20.63B vs $2.94B). GMED leads profitability with a 18.3% profit margin vs 10.1%. GEHC appears more attractively valued with a PEG of 1.70. GMED earns a higher WallStSmart Score of 74/100 (B).

GEHC

Buy

60

out of 100

Grade: C+

Growth: 4.0Profit: 7.0Value: 7.3Quality: 4.3
Piotroski: 2/9Altman Z: 1.34

GMED

Strong Buy

74

out of 100

Grade: B

Growth: 7.3Profit: 7.0Value: 10.0Quality: 7.8
Piotroski: 4/9Altman Z: 3.88
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

GEHCSignificantly Overvalued (-156.0%)

Margin of Safety

-156.0%

Fair Value

$30.94

Current Price

$72.20

$41.26 premium

UndervaluedFair: $30.94Overvalued
GMEDUndervalued (+51.9%)

Margin of Safety

+51.9%

Fair Value

$183.46

Current Price

$87.35

$96.11 discount

UndervaluedFair: $183.46Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

GEHC2 strengths · Avg: 8.5/10
Return on EquityProfitability
22.4%9/10

Every $100 of equity generates 22 in profit

P/E RatioValuation
15.6x8/10

Attractively priced relative to earnings

GMED4 strengths · Avg: 8.5/10
Altman Z-ScoreHealth
3.8810/10

Safe zone — low bankruptcy risk

Price/BookValuation
2.6x8/10

Reasonable price relative to book value

Operating MarginProfitability
24.4%8/10

Strong operational efficiency at 24.4%

Revenue GrowthGrowth
25.7%8/10

Revenue surging 25.7% year-over-year

Areas to Watch

GEHC4 concerns · Avg: 2.8/10
PEG RatioValuation
1.704/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-17.7%2/10

Earnings declined 17.7%

Altman Z-ScoreHealth
1.342/10

Distress zone — elevated risk

GMED2 concerns · Avg: 4.0/10
PEG RatioValuation
1.734/10

Expensive relative to growth rate

EPS GrowthGrowth
4.4%4/10

4.4% earnings growth

Comparative Analysis Report

WallStSmart Research

Bull Case : GEHC

The strongest argument for GEHC centers on Return on Equity, P/E Ratio.

Bull Case : GMED

The strongest argument for GMED centers on Altman Z-Score, Price/Book, Operating Margin. Profitability is solid with margins at 18.3% and operating margin at 24.4%. Revenue growth of 25.7% demonstrates continued momentum.

Bear Case : GEHC

The primary concerns for GEHC are PEG Ratio, Piotroski F-Score, EPS Growth.

Bear Case : GMED

The primary concerns for GMED are PEG Ratio, EPS Growth.

Key Dynamics to Monitor

GEHC profiles as a value stock while GMED is a growth play — different risk/reward profiles.

GEHC carries more volatility with a beta of 1.18 — expect wider price swings.

GMED is growing revenue faster at 25.7% — sustainability is the question.

GEHC generates stronger free cash flow (917M), providing more financial flexibility.

Bottom Line

GMED scores higher overall (74/100 vs 60/100), backed by strong 18.3% margins and 25.7% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

GE HealthCare Technologies Inc.

HEALTHCARE · MEDICAL DEVICES · USA

GE HealthCare Technologies Inc. provides medical technology, pharmaceutical diagnostics, and digital solutions in the United States. The company is headquartered in Chicago, Illinois.

Globus Medical

HEALTHCARE · MEDICAL DEVICES · USA

Globus Medical, Inc., a medical device company, develops and markets healthcare solutions for patients with musculoskeletal disorders. The company is headquartered in Audubon, Pennsylvania.

Want to dig deeper into these stocks?